EOLS Evolus, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001570562
AI RATING
STRONG_SELL
90% Confidence

Investment Thesis

Evolus demonstrates healthy revenue growth (11.6% YoY) and strong gross margins (66.9%), indicating viable product demand and unit economics. However, the company faces critical financial distress: negative stockholders' equity (-$28.8M), unsustainable debt load ($156.4M vs $49.8M cash), negative operating cash flow (-$10.0M), and inability to cover interest expense from operations (interest coverage -1.5x), creating acute refinancing and solvency risk.

Strengths

  • + Revenue growth of 11.6% YoY indicates sustained market demand for products
  • + Gross margin of 66.9% demonstrates strong product-level unit economics and pricing power
  • + Current ratio of 2.04x and cash position of $49.8M provide near-term liquidity buffer

Risks

  • ! Negative stockholders' equity (-$28.8M) indicates technical insolvency and liabilities exceed total assets
  • ! Debt burden of $156.4M with only $49.8M cash and negative operating cash flow creates imminent refinancing risk
  • ! Negative operating (-$6.8M) and free cash flow (-$10.4M) demonstrates business is not self-sustaining at current scale
  • ! Interest coverage ratio of -1.5x shows company cannot service debt obligations from operations

Key Metrics to Watch

Financial Metrics

Revenue
73.1M
Net Income
-10.7M
EPS (Diluted)
$-0.16
Free Cash Flow
-10.4M
Total Assets
220.6M
Cash
49.8M

Profitability Ratios

Gross Margin 66.9%
Operating Margin -9.4%
Net Margin -14.6%
ROE N/A
ROA -4.8%
FCF Margin -14.2%

Balance Sheet & Liquidity

Current Ratio
2.04x
Quick Ratio
1.68x
Debt/Equity
N/A
Debt/Assets
113.0%
Interest Coverage
-1.46x
Long-term Debt
156.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T20:20:10.023248 | Data as of: 2026-03-31 | Powered by Claude AI